Subtractive single label comparative hybridization

• US 7,892,743 B2
• Filed: 02/25/2009
• Issued: 02/22/2011
• Est. Priority Date: 07/30/2007
• Status: Active Grant

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Owen, Renius X., Strom, Charles M.
• Primary Examiner(s): WHISENANT, ETHAN C
• Application Number:
  US12/392,951
• Publication Number:
  US 20090155809A1
• Time in Patent Office: 727 Days
• Field of Search: 435/6, 536/23.1, 536/24.3
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 2521/531 Glycosylase
• CPC Class Codes: C12Q 2563/107 fluorescence
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides

Abstract

Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.

Claims

1. A method of determining a nucleotide sequence difference between nucleic acid in a test sample and nucleic acid in a reference sample, comprising:

amplifying nucleic acid from a test sample and amplifying nucleic acid from a reference sample, wherein one of the amplification reactions is conducted using dUTP and not dTTP and the other is conducted using dTTP and not dUTP;

hybridizing to a nucleic acid array a solution comprising the amplified test sample and amplified reference sample; and

determining the relative amount of hybridized test and reference nucleic acids bound to the array, wherein a difference in the relative amount of hybridized test and reference nucleic acids bound to the array identifies the presence of a nucleotide sequence difference;

wherein the sample amplified using dUTP is degraded.

2. The method of claim 1 wherein said amplified test sample is labeled with a detectable label.

3. The method of claim 1 wherein said amplified reference sample is labeled with a detectable label.

4. The method of claim 1 wherein said amplified test sample and said amplified reference sample are labeled with a detectable label.

5. The method of claim 4 wherein said amplified test and reference samples are labeled with the same detectable label.

6. The method of claim 1, wherein said test sample comprises genomic DNA.

7. The method of claim 1, wherein said test sample comprises cDNA.

8. The method of claim 5, wherein said detectable label is a flourochrome.

9. The method of claim 2, wherein said detectable label is dCTP-Cy3.

10. The method of claim 2, wherein said amplified nucleic acid is labeled with a detectable label by using a nucleotide labeled with a detectable label in the step of amplifying said test sample.

11. The method of claim 5, wherein said step of determining the relative amount of hybridized test and reference nucleic acids bound to the array comprises:

a) determining a signal for the detectable label hybridized to the array representing the total of hybridized test and reference nucleic acid;

b) treating the hybridized nucleic acids with an enzyme that selectively degrades DNA having uracil residues;

c) determining a signal for the detectable label hybridized to the array following step b), which signal represents one of said hybridized test or reference nucleic acid; and

d) determining a signal for the other of the hybridized test or reference by using the signal from a) and c).

12. The method of claim 11, wherein said enzyme that selectively degrades DNA having uracil residues is uracil-DNA N-glycosylase (LNG).

13. The method of claim 11, wherein said test sample is obtained from a patient.

14. The method of claim 11, wherein said test sample obtained from a patient is suspected of comprising cancerous cells.

15. The method of claim 11, wherein said test sample is obtained from a prenatal specimen.

16. The method of claim 11, wherein said test sample is obtained from an embryo or a fetus.

17. The method of claim 11, wherein said test sample is from an individual and the method is used to detect a genetic abnormality.

18. The method of claim 1, wherein said test sample comprises genomic nucleic acid.

19. The method of claim 1, wherein said step of determining the relative amount of hybridized test and reference nucleic acids bound to the array comprises:

a) determining the amount of nucleic acids hybridized to the array representing the total of hybridized test and reference nucleic acid;

b) treating the hybridized nucleic acids with an enzyme that selectively degrades DNA having uracil residues;

c) determining the amount of nucleic acids hybridized to the array following step b), which represents one of said hybridized test or reference nucleic acid; and

d) determining the amount of nucleic acids hybridized to the array for the other of the hybridized test or reference by using the results from a) and c).

20. The method of claim 19, wherein said enzyme that selectively degrades DNA having uracil residues is uracil-DNA N-glycosylase (UNG).